Immunovant (US.IMVT)
Capital Allocation Audit · Period: 2019 – 2026
Key Metrics
US.IMVT · YoY: 2026 ANNUAL vs 2025 ANNUAL
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -59.3% | → |
| Cash Conversion | - | → |
| D/E Ratio | 0.00 | ↑ |
| Gross Margin | - | → |
US.IMVT (Immunovant) | YoY: 2026 ANNUAL vs 2025 ANNUAL Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -59.3% → Cash Conversion - → D/E Ratio 0.00 ↑ Gross Margin - →
Key Metrics
US.IMVT (Immunovant) | YoY: 2026 ANNUAL vs 2025 ANNUAL
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -59.3% →Cash Conversion - →D/E Ratio 0.00 ↑Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies